Anti-BCMA novel therapies for multiple myeloma

Abstract

Recent advances in multiple myeloma therapy have increased the depth of response and ultimately survivals; however, the prognosis remains poor. The BCMA antigen is highly expressed in myeloma cells, thus representing a target for novel therapies. Several agents that target BCMA through different mechanisms, including bispecific T cell engagers drug conjugated to antibody and CAR-T cells, are now available or under development. Immunotherapies targeting BCMA have shown good results in efficacy and safety in multiple myeloma patients previously treated with several lines of therapy. This review will discuss the recent development of anti-BCMA targeted treatments in myeloma, with a special focus on currently available agents.

Keywords

Multiple myeloma / BCMA / belantamab / teclistamab / CART

References

[1] Rajkumar SV.Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.Am J Hematol2022;97:1086-107

[2] Paul B,Usmani SZ.BCMA-targeted biologic therapies: the next standard of care in multiple myeloma therapy.Drugs2022;82:613-31

[3] Fonseca R,Bonafede M.Trends in overall survival and costs of multiple myeloma, 2000-2014.Leukemia2017;31:1915-21

[4] Usmani SZ,Cavo M.Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG research project.Blood Cancer J2018;8:123

[5] Nishimura KK,van Rhee F.Long-term outcomes after autologous stem cell transplantation for multiple myeloma.Blood Adv2020;4:422-31

[6] Joseph NS,Dhodapkar MV.Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma.J Clin Oncol2020;38:1928-37

[7] Gozzetti A,Papini G.Therapeutic advancements in multiple myeloma.Front Oncol2014;4:241

[8] Palumbo A,Falcone A.Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results.Clin Lymphoma Myeloma2009;9:145-50

[9] Cavo M,Ronconi S.Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.Haematologica2002;87:934-42

[10] Yu B,Liu D.BCMA-targeted immunotherapy for multiple myeloma.J Hematol Oncol2020;13:125

[11] Usmani S,Ng Y.Analysis of real-world data on overall survival in multiple myeloma patients with ≥ 3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an ImiD.Oncologist2016;21:1355-61

[12] Kleber M,Terpos E.BCMA in multiple myeloma-A promising key to therapy.J Clin Med2021;10:4088

[13] Gozzetti A,Simoncelli M.Anti CD38 monoclonal antibodies for multiple myeloma treatment.Hum Vaccin Immunother2022;18:2052658

[14] Kumar SK,Kastritis E.Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.Leukemia2017;31:2443-8

[15] Gozzetti A,Lotti F.Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients.Cancer2012;118:1574-84

[16] Castillo JJ,Brozova L.IgM myeloma: a multicenter retrospective study of 134 patients.Am J Hematol2017;92:746-51

[17] Jurczyszyn A,Davila J.Prognostic indicators in primary plasma cell leukemia: a multicentre retrospective study of 117 patients.Br J Haematol2018;180:831-9

[18] Pick M,Goldschmidt N.Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis.Eur J Haematol2018;100:494-501

[19] Gandhi UH,Lakshman A.Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.Leukemia2019;33:2266-75

[20] Costa LJ,Kumar SK.Overall survival of triple class refractory, penta-exposed multiple myeloma (MM) patients treated with selinexor plus dexamethasone or conventional care: a combined analysis of the STORM and mammoth studies.Blood2019;134:3125

[21] Gozzetti A.Novel agents in CNS myeloma treatment.Cent Nerv Syst Agents Med Chem2014;14:23-7

[22] Munshi NC,Rawstron AC.Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis.JAMA Oncol2017;3:28-35

[23] Kastritis E,Eleutherakis-Papaiakovou E.Early relapse after autologous transplant is associated with very poor survival and identifies an ultra-high-risk group of patients with myeloma.Clin Lymphoma Myeloma Leuk2020;20:445-52

[24] Gozzetti A,Bacchiarri F.Minimal residual disease in multiple myeloma: state of the art and applications in clinical practice.J Pers Med2020;10:120

[25] Avigan D.Current treatment for multiple myeloma.N Engl J Med2014;371:961-2

[26] Zamagni E,Cavo M.How I treat high-risk multiple myeloma.Blood2022;139:2889-903

[27] Guo R,Zhang Y,Jin X.Targeting BCMA to treat multiple myeloma: updates from the 2021 ASH annual meeting.Front Immunol2022;13:839097

[28] Feng D.Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.Scand J Immunol2020;92:e12910

[29] Avery DT,Ellyard JI.BAFF selectively enhances the survival of plasmablasts generated from human memory B cells.J Clin Invest2003;112:286-97

[30] Madry C,Callebaut I.The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily.Int Immunol1998;10:1693-702

[31] Tai YT,An G.APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.Blood2016;127:3225-36

[32] Coquery CM.Regulatory roles of the tumor necrosis factor receptor BCMA.Crit Rev Immunol2012;32:287-305

[33] Rennert P,Cachero TG.A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth.J Exp Med2000;192:1677-84

[34] Demchenko YN,Zingone A,Bergsagel PL.Classical and/or alternative NF-kappaB pathway activation in multiple myeloma.Blood2010;115:3541-52

[35] Moreaux J,Jourdan E.BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.Blood2004;103:3148-57

[36] Shen X,Qi J,Wu X.Binding of B-cell maturation antigen to B-cell activating factor induces survival of multiple myeloma cells by activating Akt and JNK signaling pathways.Cell Biochem Funct2016;34:104-10

[37] Hatzoglou A,Bourgeade MF.TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase.J Immunol2000;165:1322-30

[38] O'Connor BP,Erickson LD.BCMA is essential for the survival of long-lived bone marrow plasma cells.J Exp Med2004;199:91-8

[39] Xu S.B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses.Mol Cell Biol2001;21:4067-74

[40] Carpenter RO,Pittaluga S.B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.Clin Cancer Res2013;19:2048-60

[41] Sanchez E,Kitto A.Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival.Br J Haematol2012;158:727-38

[42] Yaccoby S,Li X.Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts.Leukemia2008;22:406-13

[43] Lin L,Wen K.Impacts of a proliferation-inducing ligand on current therapeutic monoclonal antibody-induced cytotoxicity against human multiple myeloma cells.Blood2019;134:3105

[44] Laurent SA,Kuhn PH.γ-Secretase directly sheds the survival receptor BCMA from plasma cells.Nat Commun2015;6:7333

[45] Ghermezi M,Vardanyan S.Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients.Haematologica2017;102:785-95

[46] Gavriatopoulou M,Dimopoulos MA.Anti-BCMA antibodies in the future management of multiple myeloma.Expert Rev Anticancer Ther2019;19:319-26

[47] Ali SA,Maric I.T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.Blood2016;128:1688-700

[48] Martino M.An update on B-cell maturation antigen-targeted therapies in multiple myeloma.Expert Opin Biol Ther2021;21:1025-34

[49] Visram A,Rajkumar SV.Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients.Blood Cancer J2021;11:120

[50] Sanchez E,Tang G.Soluble B-Cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma.Clin Cancer Res2016;22:3383-97

[51] Chen H,Xu N.Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells.Leuk Res2019;81:62-6

[52] Pont MJ,Cole GO.γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.Blood2019;134:1585-97

[53] Sherbenou DW,Su Y,Martin TG 3rd.The development of potential antibody-based therapies for myeloma.Blood Rev2015;29:81-91

[54] Shah N,Scott E,Usmani SZ.B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.Leukemia2020;34:985-1005

[55] Bruins WSC,Mutis T.Targeted therapy with immunoconjugates for multiple myeloma.Front Immunol2020;11:1155

[56] Pahl A,Hechler T.Amanitins and their development as a payload for antibody-drug conjugates.Drug Discov Today Technol2018;30:85-9

[57] Bera TK.Anti-BCMA immunotoxins: design, production, and preclinical evaluation.Biomolecules2020;10:1387

[58] McCombs JR.Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry.AAPS J2015;17:339-51

[59] Yu B.Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma.J Hematol Oncol2019;12:94

[60] Abdollahpour-Alitappeh M,Gharibi T.Antibody-drug conjugates (ADCs) for cancer therapy: strategies, challenges, and successes.J Cell Physiol2019;234:5628-42

[61] Tai YT,Acharya C.Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.Blood2014;123:3128-38

[62] Sheikh S,Trudel S.Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma.Future Oncol2020;16:2783-98

[63] Markham A.Belantamab mafodotin: first approval.Drugs2020;80:1607-13

[64] Eastman S,Gupta I,Blackwell C.Synergistic activity of belantamab mafodotin (anti-BCMA immuno-conjugate) with PF-03084014 (gamma-secretase inhibitor) in Bcma-expressing cancer cell lines.Blood2019;134:4401

[65] Montes de Oca R,Vitali N.Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo.Mol Cancer Ther2021;20:1941-55

[66] Trudel S,Popat R.Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.Lancet Oncol2018;19:1641-53

[67] Trudel S,Popat R.Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study.Blood Cancer J2019;9:37

[68] Lonial S,Badros A.Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.Cancer2021;127:4198-212

[69] Lonial S,Badros A.Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.Lancet Oncol2020;21:207-21

[70] Richardson PG,Abdallah AO.Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study.Blood Cancer J2020;10:106

[71] Wahab A,Mushtaq K.Ocular toxicity of belantamab mafodotin, an oncological perspective of management in relapsed and refractory multiple myeloma.Front Oncol2021;11:678634

[72] Offidani M,Morè S.Belantamab mafodotin for the treatment of multiple myeloma: an overview of the clinical efficacy and safety.Drug Des Devel Ther2021;15:2401-15

[73] Nooka AK,van de Donk NW.Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.Future Oncol2021;17:1987-2003

[74] O’Donnell EK.New monoclonal antibodies on the horizon in multiple myeloma.Ther Adv Hematol2017;8:41-53

[75] Lee HC,Landgren O.Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma.Leukemia2021;35:255-8

[76] Figueroa-Vazquez V,Breunig C.HDP-101, an anti-BCMA antibody-drug conjugate, safely delivers amanitin to induce cell death in proliferating and resting multiple myeloma cells.Mol Cancer Ther2021;20:367-78

[77] Suurs FV,de Vries EGE.A review of bispecific antibodies and antibody constructs in oncology and clinical challenges.Pharmacol Ther2019;201:103-19

[78] Offner S,Romaniuk A,Baeuerle PA.Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells.Mol Immunol2006;43:763-71

[79] Fan G,Hao M.Bispecific antibodies and their applications.J Hematol Oncol2015;8:130

[80] Ravi G.Bispecific T-cell engagers for treatment of multiple myeloma.Am J Hematol2023;98:S13-S21

[81] Shimabukuro-Vornhagen A,Subklewe M.Cytokine release syndrome.J Immunother Cancer2018;6:56

[82] Lee DW,Porter DL.Current concepts in the diagnosis and management of cytokine release syndrome.Blood2014;124:188-95

[83] Pillarisetti K,Luistro L.Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma.Blood Adv2020;4:4538-49

[84] Usmani SZ,van de Donk NWCJ.Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.Lancet2021;398:665-74

[85] Moreau P,van de Donk NWCJ.Teclistamab in relapsed or refractory multiple myeloma.N Engl J Med2022;387:495-505

[86] Girgis S,Pillarisetti K.Translational modeling predicts efficacious therapeutic dosing range of teclistamab for multiple myeloma.Target Oncol2022;17:433-9

[87] Mullard A.BCMA-targeted bispecific gets first green light, in the EU.Nat Rev Drug Discov2022;21:626

[88] Caraccio C,Phillips DJ.Bispecific antibodies for multiple myeloma: a review of targets, drugs, clinical trials, and future directions.Front Immunol2020;11:501

[89] DiLillo DJ,Mohrs K.A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.Blood Adv2021;5:1291-304

[90] Clarke SC,Trinklein ND.Multispecific antibody development platform based on human heavy chain antibodies.Front Immunol2019;9:3037

[91] Sebag M,Bahlis NJ.Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-Engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: results from Magnetismm-1.Blood2021;138:895

[92] Harris KE,Davison LM.Sequence-based discovery demonstrates that fixed light chain human transgenic rats produce a diverse repertoire of antigen-specific antibodies.Front Immunol2018;9:889

[93] Buelow B,Rodriguez C.TNB383B. 0001: a multicenter, phase 1, open-label, dose-escalation andexpansion study of TNB-383B, a bispecific antibodytargeting BCMA in subjects with relapsed or refractorymultiple myeloma.Blood2019;134:1874

[94] Kumar S,Shah N.A phase 1 first-in-human study of Tnb-383B, a BCMA x CD3 bispecific T-Cell redirecting antibody, in patients with relapsed/refractory multiple myeloma.Blood2021;138:900

[95] Harrison SJ,Lee HC.A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE®(bispecific T-cell engager) molecule, in relapsed/refractory (RR) multiple myeloma (MM).Blood2020;136:28-9

[96] Costa LJ,Bermúdez A.First clinical study of the B-cell maturation antigen (BCMA) 2 + 1 T cell engager (TCE) CC-93269 in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial.Blood2019;134:143

[97] Vrohlings M,Jungmichel S.Preclinical assessment of CDR101-a BCMAxCD3xPD-L1 trispecific antibody with superior anti-tumor efficacy.Blood2021;138:1583

[98] Jayaraman J,Hou AJ.CAR-T design: elements and their synergistic function.EBioMedicine2020;58:102931

[99] Sadelain M,Rivière I.The basic principles of chimeric antigen receptor design.Cancer Discov2013;3:388-98

[100] de Donk NWCJ, Usmani SZ, Yong K. CAR T-cell therapy for multiple myeloma: state of the art and prospects.Lancet Haematol2021;8:e446-61

[101] Song DG,Poussin M,Figini M.CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.Blood2012;119:696-706

[102] Rafiq S,Brentjens RJ.Engineering strategies to overcome the current roadblocks in CAR T cell therapy.Nat Rev Clin Oncol2020;17:147-67

[103] Mikkilineni L.Chimeric antigen receptor T-cell therapies for multiple myeloma.Blood2017;130:2594-602

[104] Suryadevara CM,Farber SH.Preventing Lck activation in CAR T cells confers treg resistance but requires 4-1BB signaling for them to persist and treat solid tumors in nonlymphodepleted hosts.Clin Cancer Res2019;25:358-68

[105] Gattinoni L,Klebanoff CA.Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8⁺ T cells.J Exp Med2005;202:907-12

[106] Nobari ST,Talebi M.B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages.J Transl Med2022;20:82

[107] Friedman KM,Evans JW.Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells.Hum Gene Ther2018;29:585-601

[108] Bu DX,Choi EE.Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma.Oncotarget2018;9:25764-80

[109] Xu J,Yang SS.Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.Proc Natl Acad Sci USA2019;116:9543-51

[110] Kang L,Li M.Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma.Biomark Res2020;8:14

[111] Zhang H,Liu L.A Bcma and CD19 bispecific CAR-T for relapsed and refractory multiple myeloma.Blood134:3147

[112] Mei H,Jiang H.A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.J Hematol Oncol2021;14:1-7

[113] Manier S,Escure G.Current state and next-generation CAR-T cells in multiple myeloma.Blood Rev2022;54:100929

[114] Roex G,Flumens D.Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells.J Transl Med2022;20:124

[115] Depil S,Grupp SA,Poirot L.“Off-the-shelf” allogeneic CAR T cells: development and challenges.Nat Rev Drug Discov2020;19:185-99

[116] Graham C,Pepper A.Allogeneic CAR-T cells: more than ease of access?.Cells2018;7:155

[117] Sommer C,Kuo TC.Preclinical evaluation of allogeneic CAR T cells targeting BCMA for the treatment of multiple myeloma.Mol Ther2019;27:1126-38

[118] Mailankody S,Liedtke M.Universal: an allogeneic first-in-human study of the anti-BCMA ALLO-715 and the anti-CD52 ALLO-647 in relapsed/refractory multiple myeloma.Blood2020;136:24-5

[119] Gong Y,Wang J,Germeraad WTV.Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.J Hematol Oncol2021;14:73

[120] Williams RL,Bachanova V.Recipient T cell exhaustion and successful adoptive transfer of haploidentical natural killer cells.Biol Blood Marrow Transplant2018;24:618-22

[121] Martín EM,García-Ortiz A.Exploring NKG2D and BCMA-CAR NK-92 for adoptive cellular therapy to multiple myeloma.Clin Lymphoma Myeloma Leuk2019;19:e24-5

[122] Raje N,Lin Y.Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.N Engl J Med2019;380:1726-37

[123] Munshi NC,Shah N.Idecabtagene vicleucel in relapsed and refractory multiple myeloma.N Engl J Med2021;384:705-16

[124] Anderson LD Jr.Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.Future Oncol2022;18:277-89

[125] Oriol A,Torrent A,Ribera JM.The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma.Ther Adv Hematol2021;12:20406207211019622

[126] Delforge M,Cavo M.KarMMa-3: a phase 3 study of idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy vs standard regimens in relapsed and refractory multiple myeloma.Blood2020;136:24-5

[127] Usmani SZ,Truppel-Hartmann A.KarMMa-4: idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, in high-risk newly diagnosed multiple myeloma.Blood2020;136:18-9

[128] Zhao WH,Wang BY.A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.J Hematol Oncol2018;11:141

[129] Berdeja JG,Usmani SZ.Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.Lancet2021;398:314-24

[130] Martin T,Berdeja JG.Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up.J Clin Oncol2022;41:JCO.2200842

[131] Cohen YC,Delforge M.Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma after 1-3 prior lines of therapy: updated results from CARTITUDE-2.Blood2021;138:3866

[132] Dytfeld D,Agha M.Bortezomib, lenalidomide and dexamethasone (VRd) followed by ciltacabtagene autoleucel versus Vrd followed by lenalidomide and dexamethasone (Rd) maintenance in patients with newly diagnosed multiple myeloma not intended for transplant: a randomized, phase 3 study (CARTITUDE-5).Blood2021;138:1835

[133] Gozzetti A,Sicuranza A.Drug resistance and minimal residual disease in multiple myeloma.Cancer Drug Resist2022;5:171-83

[134] Zamagni E,Gay F et al.MRD evaluation by PET/CT according to deauville criteria combined with multiparameter flow cytometry in newly diagnosed transplant eligible multiple myeloma (MM) patients enrolled in the phase II randomized forte trial.Blood2019;134:4321

[135] Zinzani P.L, Zompatori M, Bendandi M, et al. Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin’s disease and high-grade non-Hodgkin’slymphoma.Leuk Lymphoma1996;22:131-5

[136] Hillengass J,Rajkumar SV et al.International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.Lancet Oncol2019;20:e346

[137] Cencini E,Sicuranza A,Bocchia M.The role of tumor-associated macrophages in hematologic malignancies.Cancers2021;13:3597

[138] Majzner RG.Tumor antigen escape from CAR T-cell therapy.Cancer Discov2018;8:1219-26

[139] de Donk NWCJ, Themeli M, Usmani SZ. Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma.Blood Cancer Discov2021;2:302-18 PMCID:PMC8357299

[140] Shah NN.Mechanisms of resistance to CAR T cell therapy.Nat Rev Clin Oncol2019;16:372-85

[141] Atilla PA.Resistance against anti-CD19 and anti-BCMA CAR T cells: recent advances and coping strategies.Transl Oncol2022;22:101459

[142] Rafiq S,Jackson HJ.Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo.Nat Biotechnol2018;36:847-56